54TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2025 ONESOURCE Neeraj Sharma is CEO of Onesource, a global specialty CDMO with end-to-end capabilities in Drug-device combinations, Complex injectables, Biologics and oral technologies. In a discussion with 24/7 Biopharma at CPHI Milan, Sharma opened up about his company’s core strength and how industry tailwinds are propelling the company further in its journey. When asked about Onesource’s unique value proposition, Sharma pointed to the diversity of services they offer. While he noted that the company may not have the track record of the established big players in some segments, he feels that the company’s “width” of offerings and end to end differentiates it from the herd. A perfect track record in quality and compliance with over 100 customer and regulatory audits, agility and willingness to provide customized solution and investment in state-of-the-art facility for biologics and DDC has enabled OneSource to attract global customers. Company’s biggest draw is their work with drug-device combinations, a technically difficult area to operate in due to the scale of fill-finish and the complexity of the assembly process. “The biggest part of this value chain is a device itself, and the maximum complexity is around assembling the device, putting the cartridge or a pre-filled syringe into a pen or an auto-injector [and] testing it,” said Sharma. “Because what FDA or EMA look for in a drug device, the maximum time for review is the device itself, and how accurate it’s actually dispensing the drug. And that’s where our expertise is, that we are able to assemble it, we are able to put it together, test it. And that trust is why we have got multiple customers for drug device combinations.”
RkJQdWJsaXNoZXIy MjY2OTA4MA==